Actively Recruiting
Open-label Study to Assess Safety and Tolerability of Lumateperone in Children and Adolescents With Schizophrenia, Bipolar Disorder, or Autism Spectrum Disorder
Led by Intra-Cellular Therapies, Inc. · Updated on 2026-11-03
300
Participants Needed
65
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of lumateperone in children and adolescents diagnosed with schizophrenia, bipolar disorder, or autism spectrum disorder. This open-label, multicenter study lasts 26 weeks and aims to better understand how this medication affects pediatric patients with these conditions. The study includes patients who are either new to treatment or rolling over from previous related studies. Participants will receive lumateperone once daily in capsule or orally disintegrating tablet form, with doses ranging from 5 mg to 42 mg based on their age and condition. The trial begins with a screening period up to 2 weeks to confirm eligibility, followed by a 26-week treatment phase where all participants receive open-label lumateperone. After treatment, there is a 2-week safety follow-up visit approximately 2 weeks after the last dose. Throughout the study, participants will attend clinic visits for monitoring and assessments. Researchers will collect safety data, including tracking common adverse events up to six months. Patients must be outpatients expected to remain so during the study. Safety follow-up helps ensure ongoing monitoring after treatment ends, with the entire participation lasting about 28 weeks including screening and follow-up.
CONDITIONS
Brief Title
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here